|
|
Article: Observational analysis: Risedronate reduced nonvertebral fracture risk.
- Article from:
- Genomics & Genetics Weekly
- Article date:
- October 31, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 OCT 31 - (NewsRx.com & NewsRx.net) -- In an observational analysis presented at the 25th annual meeting of the American Society for Bone and Mineral Research (ASBMR), osteoporosis patients taking risedronate (Actonel) had a 59% (p=0.04) lower risk of nonvertebral fracture than patients receiving alendronate (Fosamax), and a 75% (p
"Fracture reduction is the clinically relevant endpoint for evaluating osteoporosis therapies," said Nelson B. Watts, MD, presenting author and director, University of Cincinnati Bone Health and Osteoporosis Center. "While only head-to-head clinical trials comparing fracture efficacy can confirm differences in efficacy between osteoporosis ...